Atea's HCV Drug Shows Favorable Drug-Drug Interaction Profile; HEV Candidate Advances to First-in-Human
AVIR sits 58% above its 52-week low of $2.78.
Summary
Atea Pharmaceuticals presented positive Phase 1 results for its hepatitis C virus (HCV) regimen, bemnifosbuvir and ruzasvir (BEM/RZR), at the EASL Congress. The data showed a low risk of drug-drug interactions, supporting co-administration with common medications like PPIs, which is a significant advantage for patient care and market adoption. Additionally, the company presented promising preclinical data for AT-587, a potential first-in-class direct-acting antiviral for hepatitis E virus (HEV), an area with no approved therapies. Atea plans to advance AT-587 into a first-in-human study mid-year. This pipeline progress is crucial for the company, especially following its recent Q1 report showing increased R&D spending. Topline Phase 3 results for BEM/RZR from the C-BEYOND and C-FORWARD studies are expected, which will be a key event to watch.
At the time of this announcement, AVIR was trading at $4.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $362.5M. The 52-week trading range was $2.78 to $6.45. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.